Nanjing Medlander Medical Technology Co. Ltd. A

Medlander released its 2026 interim report. Total operating revenue was 193 million yuan, down 20.02% year on year. Net profit attributable to the parent company was 36.7306 million yuan, down 42.54% year on year. Net cash flow from operating activities was negative 9.7186 million yuan, down 133.30% year on year. The company's asset-liability ratio was 15.85%, gross margin was 66.64%, ROE was 2.75%, and diluted earnings per share was 0.38 yuan.

Medlander released its 2026 interim report. In the first half, the company's operating revenue was 193 million yuan, down 20.0% year on year. Net profit attributable to the parent was 36.73 million yuan, down 42.5%. Non-GAAP net profit attributable to the parent was 33.71 million yuan, down 44.5%. Net operating cash flow was negative 9.72 million yuan, down 133.3% year on year. Earnings per share were 0.3673 yuan. In the second quarter, operating revenue was 93.73 million yuan, down 23.8% year on year, and net profit attributable to the parent was 13.81 million yuan, down 42.6%. As of the end of the second quarter, the company's total assets were 1.612 billion yuan, down 1.1% from the end of the previous year. Net assets attributable to the parent were 1.335 billion yuan, down 0.7% from the end of the previous year. The company said it continues to expand its product line in pelvic floor and obstetric rehabilitation, launching multiple new products, with research and development expenses accounting for 15.68% of operating revenue, while also facing intensifying market competition.